IL-36B Antibody
| Code | Size | Price |
|---|
| PSI-7507-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7507-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
IL-36B Antibody: FIL1, FIL1H, IL1F8, IL1H2, IL-1F8, IL-1H2, IL1-ETA, FIL1-(ETA), FILI-(ETA), Interleukin-36 beta, FIL1 eta, IL-1 eta
Application Note:
IL-36B antibody can be used for detection of IL-36B by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
IL-36B is is a member of the interleukin 1 cytokine family whose gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2 (1). IL-36B is thought to activate the NF-kappaB pathway through IL-1 receptor family members IL-1RL2 and IL-1RAcP (2). Like the related proteins IL-36A and IL-36G, IL-36B requires post-translational processing for full agonist activity, but the cleavage mechanism is currently unknown (3). The IL-36 cytokines have been suggested to amplify Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells (4).
Background References:
- Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 2000; 275:1169-75.
- Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 2004; 279:13677-88.
- Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist agonist (IL-36a, IL-36b, and IL-36g) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011; 286:42594-602.
- Vigne S, Palmer G, Martin P, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012; 120:3478-87.
Buffer:
IL-36B antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IL-36B antibody was raised against a 16 amino acid peptide near the carboxy terminus of human IL-36B.
The immunogen is located within the last 50 amino acids of IL-36B.
The immunogen is located within the last 50 amino acids of IL-36B.
NCBI Gene ID #:
27177
NCBI Official Name:
interleukin 36, beta
NCBI Official Symbol:
IL36B
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 18 kDa
Observed: 17 kDa
Observed: 17 kDa
Protein Accession #:
NP_055253
Protein GI Number:
20070252
Purification:
IL-36B antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
SPECIFICITY:
IL-36B antibody is human specific. At least two isoforms of IL-36B are known to exist; this antibody will only detect the longer isoform. IL-36B antibody will not cross-react with IL-36A or IL-36G.
Swissprot #:
Q9NZH7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | IL-36B Peptide | PSI-7507P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|